Rabbit Polyclonal FZD2 Antibody

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human renal cancer tissue using P04240(FZD2 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The FZD2 antibody targets Frizzled class receptor 2 (FZD2), a member of the Frizzled family of G protein-coupled receptors that serve as key receptors for Wnt signaling pathways. FZD2 plays a critical role in regulating Wnt/β-catenin and non-canonical Wnt pathways, influencing processes like embryonic development, cell polarity, proliferation, and tissue homeostasis. Dysregulation of FZD2 is linked to cancers (e.g., hepatocellular carcinoma, breast cancer) and fibrotic diseases, where its overexpression often correlates with tumor progression, metastasis, or abnormal tissue remodeling.

FZD2 antibodies are essential tools for detecting FZD2 protein expression in research applications such as Western blotting, immunohistochemistry (IHC), and flow cytometry. They help elucidate FZD2's functional roles, localization, and interaction with Wnt ligands or co-receptors like LRP5/6. Both monoclonal and polyclonal variants are available, with monoclonal antibodies offering higher specificity for precise detection. Challenges include potential cross-reactivity with other Frizzled family members due to structural homology. Commercially, FZD2 antibodies are offered by companies like Abcam and Cell Signaling Technology, often validated for specific experimental conditions. Their therapeutic potential is also being explored, particularly in blocking oncogenic Wnt signaling in cancer.